Stewart Thomas Carlton sold $3K of CGC

Stewart Thomas Carlton (See Remarks) sold 2,231 shares of Canopy Growth Corp (CGC) at $1.47 on 2026-08-24.

Original reporting
SEC EDGAR · Stewart Thomas Carlton
Published Aug 25, 2026, 9:40 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 25, 2026, 9:41 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CGC
Neutral
high confidence
Mentioned
$CGC
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CGCNeutralLow
01

Why it matters

The sale is minor and does not suggest material information; likely routine portfolio rebalancing.

02

Market read

Low relevance; the filing provides a new data point but lacks material impact.

03

What to watch

Potential upcoming corporate actions or financing that may prompt larger insider activity.

Relevance 3/10Novelty 4/10Timing: post-market filing on 2026-08-24

Background

Form 4 filings disclose insider trades; investors track them for signals of insider sentiment.

Company-level read

Ticker impact

$CGCNeutralHigh confidence
Context

Officer Stewart Thomas Carlton sold 2,231 shares of Canopy Growth at $1.47 each, total $3,279.57.

Expected impact

minimal impact, price likely unchanged

Evidence & confidence

The transaction size is trivial relative to market cap and typical daily volume.

Market effects

None; cannabis sector not affected by this small insider transaction.

No regional impact.

Insignificant.

Counterpoint

Even small insider sales can signal lack of confidence; monitor for larger future disposals.

Key entities

  • Canopy Growth Corp

    Canadian cannabis producer listed on NYSE under CGC.

  • Stewart Thomas Carlton

    Company officer who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CGCMed

Canopy Growth (CGC) Q2 2027 Earnings Call Transcript

Canopy Growth (CGC) reported Q2 2027 revenue of $81.4M, up 22% YoY, driven by 30% cannabis segment growth. Medical cannabis and international markets showed momentum, while Storz & Bickel revenue fell 44% YoY to $50.1M. The company expects improved yields and EU GMP certifications to boost growth and margins. Adjusted EBITDA loss narrowed to $2.9M, with a target of profitability in H2 2027.

$CGCMedAI 8/10

Canopy Growth Corporation Q2 2027 Earnings Call Summary

Canopy Growth reported Q2 2027 results, highlighting a 141% YoY increase in international cannabis revenue and a 44% decline in Storz & Bickel revenue due to economic uncertainty. The company aims for positive adjusted EBITDA in H2 2027, with cultivation improvements expected to boost flower production by 25-30% in early 2028. Canopy also secured EU GMP certification, enabling expansion into European markets beyond dry flower.

$CGCMed

Canopy Growth Q2 Earnings Call Highlights

Canopy Growth reported Q2 revenue growth in Canada and plans to build a dedicated sales force. Storz & Bickel revenue declined 4% but expects a strong Q3. Cultivation improvements aim for 25-30% yield increase. Adjusted gross margin fell to 31% from 33% due to VA reimbursement rate changes. Cash reserves were CAD 320 million as of September 30. The company may pursue a reverse stock split to maintain Nasdaq compliance.